
Krebs Biochemicals & Industries Ltd Downgraded to Sell Amid Mixed Technicals and Weak Fundamentals
2026-11-17 08:31:28Krebs Biochemicals & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 Nov 2026, driven primarily by improvements in technical indicators despite persistent fundamental weaknesses. The company’s micro-cap status and challenging financial trends continue to weigh on its outlook, but recent technical signals have prompted a more favourable stance from analysts.
Read More
Krebs Biochemicals & Industries Ltd Forms Golden Cross Amid Mixed Technical Signals
2026-11-16 18:00:11The 50-day moving average has crossed above the 200-day moving average for Krebs Biochemicals & Industries Ltd, signalling a golden cross on 16 Nov 2026. Yet, the stock’s modest 0.20% gain on the day and a patchwork of technical indicators suggest the signal is far from straightforward — is this a genuine shift in momentum or a lone signal amid mixed evidence?
Read More
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
2026-10-31 10:10:13Krebs Biochemicals & Industries Ltd is rated 'Strong Sell' by MarketsMOJO, a rating that was last updated on 06 February 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 31 October 2026, providing investors with an up-to-date perspective on its performance and outlook.
Read More
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
2026-10-09 10:10:40Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 09 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall market standing.
Read More
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
2026-09-28 10:10:37Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 28 September 2026, providing investors with the latest insights into its performance and outlook.
Read More
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
2026-09-16 10:10:36Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 16 September 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.
Read More
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
2026-09-02 10:10:26Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the company's current position as of 02 September 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trend, and technical outlook.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
30-Oct-2026 | Source : BSEThe Company has enclosed herewith copy of newspaper advertiement for financial results for the quarter ended 30.09.2026
Result For The Quarter Ended 30.09.2026
29-Oct-2026 | Source : BSEFinancial Results for the quarter ended 30.09.2026
Board Meeting Outcome for Outcome Of Board Meeting Held On 29.10.2026
29-Oct-2026 | Source : BSEOutcome of the Board Meeting for consideration of unaudited financial results for the quarter ended 30.09.2026
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
Krebs Biochemicals & Industries Ltd has announced 21:100 rights issue, ex-date: 31 Jan 19